Skip to main content

Drug Interactions between ferric carboxymaltose and PNV-OB with DHA

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

multivitamin, prenatal ferric carboxymaltose

Applies to: PNV-OB with DHA (multivitamin, prenatal) and ferric carboxymaltose

GENERALLY AVOID: Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations.

MANAGEMENT: Parenteral iron preparations should not be administered concomitantly with oral iron preparations. Patients should wait at least 5 days after stopping parenteral iron therapy before taking oral iron supplements.

References

  1. "Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc
  2. (2001) "Product Information. Ferrlecit (sodium ferric gluconate complex)." sanofi-aventis
  3. (2001) "Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc
  4. (2009) "Product Information. Feraheme (ferumoxytol)." Alza Pharmaceuticals
  5. (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics
View all 5 references

Switch to consumer interaction data

Drug and food interactions

Moderate

multivitamin, prenatal food

Applies to: PNV-OB with DHA (multivitamin, prenatal)

ADJUST DOSING INTERVAL: Concomitant use of some oral medications may reduce the bioavailability of orally administered iron, and vice versa.

Food taken in conjunction with oral iron supplements may reduce the bioavailability of the iron. However, in many patients intolerable gastrointestinal side effects occur necessitating administration with food.

MANAGEMENT: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.

References

  1. "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
  2. (2021) "Product Information. Accrufer (ferric maltol)." Shield Therapeutics

Switch to consumer interaction data

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Iron preparations

Therapeutic duplication

The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'iron preparations' category:

  • ferric carboxymaltose
  • PNV-OB with DHA (multivitamin, prenatal)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer